secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000944809-22-000023
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q1 net loss $55.4M; completes ModeX acquisition for $300M and GeneDx sale
--------------------------------------------------------------------------------

- Q1 consolidated revenue $329.2M (down from $545.2M); net loss $55.4M ($0.08) vs net income $31.1M ($0.05) prior year.
- Diagnostics revenue $286.6M (down from $507.0M) due to lower COVID-19 testing: 2.0M tests vs 4.1M YoY.
- Acquired ModeX Therapeutics for $300M in OPKO common stock; Dr. Elias Zerhouni named President and Vice Chairman.
- Closed sale of GeneDx to Sema4 for ~$322M upfront (cash + stock) plus up to $150M in milestones.
- Pfizer launched NGENLA in Germany/Japan; OPKO earned $85M milestones. RAYALDEE launched in Germany by Vifor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000023/0000944809-22-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000023/opk-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000944809-22-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer